Du är här

2016-01-26

DBV Technologies: DBV Technologies Proudly Welcomes Edward Jordan as Senior Vice President Commercial Operations North America

--------------------------------------
| Press Release |
| |
|Montrouge, France, 26 January, 2016 |
--------------------------------------

DBV Technologies Proudly WelcomesEdward Jordan as Senior Vice President Commercial Operations North AmericaDBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market:
DBVT), a clinical-stage specialty biopharmaceutical company, today announced
the appointment of Edward Jordan as Senior Vice President, Commercial
Operations North America, effective January 4, 2016. Mr. Jordan will be
responsible for leading the company's commercial functions in North America.

Charles Ruban
, Chief Commercial Officer of DBV Technologies said:"Edward has an outstanding
track record of success in biopharmaceutical sales
and marketing, and he joins DBV at an important time in our company's growth.
Mr. Ruban
continued, "His product launch experience and deep industry expertise will be
great assets as we prepare for the commercialization of our Viaskin®
products, including our two lead product candidates, Viaskin® Peanut and
Viaskin® Milk."

"DBV's Viaskin® technology has the potential to transform immunotherapy with
its novel, science-driven and clinically validated platform. I am thrilled to
be joining a company that can have a fundamental and significant impact on
the life of patients suffering from food allergies,"
Mr. Jordan
stated,"As we prepare for the potential launch of Viaskin® Peanut, I look
forward to
building a team that shares our commitment to finding safe, effective and
patient-friendly treatments for food allergies.
"

Mr. Jordan brings to DBV more than 20 years of commercial leadership and
product launch experience in both prescription and over-the-counter (OTC)
products. Prior to joining DBV, Mr. Jordan served as Senior Vice President,
Commercial Operations at AMAG Pharmaceuticals, Inc. In that role, he oversaw
commercialization strategies and execution for the global Hematology/Oncology
business, which generated double-digit revenue growth during his tenure. In a
prior role at Teva Pharmaceuticals, Mr. Jordan served as Head of Sales,
Marketing, Training&Effectiveness, Women's Health Care. He led a team of more
than 250 individuals who drove steady growth in prescription, device and OTC
sales, and successfully launched new products in both the prescription and
OTC arenas. Earlier in his career, Mr. Jordan held a series of global
development and leadership roles for the pharmaceutical business at
Schering-Plough Corporation (now Merck). During his 17 years at
Schering-Plough, he gained extensive allergy experience with multiple
products at varying stages in their lifecycles. As Senior Director of
International Operations, Mr. Jordan engineered enhancements to financial
planning, promotional strategies, launch excellence and operational
effectiveness, optimizing profitability and ensuring the consistent and
effective deployment of global brands across countries.

Mr. Jordan earned an MBA from Southern New Hampshire University, and dual
Bachelor of Science degrees in finance and insurance from the University of
Rhode Island.

About DBV Technologies

DBV Technologies is developing Viaskin®, an innovative new approach to the
treatment of allergies - a major public health issue that has been increasing
in prevalence. DBV Technologies, incorporated in France in 2002, has
developed a proprietary, patented technology for administering an allergen to
intact skin while avoiding transfer to the blood, and thus lowering the risk
of a systemic, allergic reaction in the event of accidental exposure. DBV
Technologies is focusing on food allergies, including milk and peanut, for
which there are currently no effective treatments. DBV Technologies has
designed two products candidates: Viaskin® Peanut and Viaskin® Milk. The
clinical development program for Viaskin® Peanut has received Fast Track
designation and Breakthrough Therapy designation from the U.S. Food and Drug
Administration.

DBV Technologies shares are traded on segment B of Euronext Paris (Ticker:
DBV, ISIN code: FR0010417345) and on the Nasdaq Stock Market in the form of
American Depositary Shares (each representing one-half of one ordinary share)
(Ticker: DBVT). For more information on DBV Technologies, please visit our
website:www.dbv-technologies.com

Forward Looking Statements

This press release contains forward-looking statements forward-looking
statements that are not promises or guarantees and involve substantial risks
and uncertainties. The Company's product candidates have not been approved
for sale in any jurisdiction. Among the factors that could cause actual
results to differ materially from those described or projected herein are
uncertainties associated generally with research and development, clinical
trials and related regulatory reviews and approvals, the risk that historical
preclinical results may not be predictive of future clinical trial results,
and the risk that historical clinical trial results may not be predictive of
future trial results. A further list and description of these risks,
uncertainties and other risks can be found in the Company's regulatory
filings with the French Autorité des Marchés Financiers, the Company's
Securities and Exchange Commission filings and reports, including in the
Company's Annual Report on Form 20-F for the year ended December 31, 2014 and
future filings and reports by the Company. Existing and prospective
investors are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. DBV Technologies
undertakes no obligation to update or revise the information contained in
this Press Release, whether as a result of new information, future events or
circumstances or otherwise.

----------------------------------------------------------------------------------------------------
| DBV Technologies Contacts |
| Nathalie Donne Susanna Mesa |
| |
| VP Finance, US Investor Relations&Strategy |
|Director, Corporate Communication&Business Development Tél. : +1 917-346-3447 |
| susanna.mesa@dbv-technologies.com |
|Tél. : +33(0)1 55 42 78 72 |
|nathalie.donne@dbv-technologies.com |
| DBV Technologies Media Contacts US&Europe |
| Marion Janic Caroline Carmagnol |
| |
| |
|Rooney&Associates Alize RP - Relation Presse |
| |
|Tél. : +1-212-223-4017 Tél. : +33(0)6 64 18 99 59 |
|mjanic@rooneyco.com |
| caroline@alizerp.com |
----------------------------------------------------------------------------------------------------
PDF Version
http://hugin.info/156437/R/1981165/725821.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: DBV Technologies via Globenewswire

HUG#1981165

Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.